BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
If evolution is real, then why isn’t it happening now? An anthropologist explains that humans actually are still evolving - 2This St Nick Truly Can Advise How To Drink And Hack Your Headache
- 3Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- 4Make your choice for a definitive Christmas place to get-away!
- 510 Natural products to Remember for Your Eating routine for a Better You
- Vote In favor of Your Favored Language Interpretation Administration
- Avoid Slam: Exploring the Pickup Truck Transformation
- Most loved Road Food: Which One Prevails upon You?
- Most loved Real time feature: Which Stage Do You Like
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Most loved Occasion Dish: What Makes Your Merry Table?
- Best Augmented Simulation Ride: Which One Feels Generally Genuine?
- Monetary Freedom Guide: Plan Your Future
- America's Confided in Cooler in 2024
